Earnings

Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate

Aug 11, 2026 · 04:40 PM ET· updated 1h ago

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 33.33 percent increase over losses of $(0.21) per share from

Why It Matters

Cardiff Oncology lost less money than people expected this quarter, and made more sales than predicted. When a company beats expectations, even while losing money, it shows the business is moving in a better direction.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CRDF1.03

-0.01 (-0.49%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.